| Prospective cohorta | Combined cohortb | ||
---|---|---|---|---|
Non-regular user | Regular user | Non-regular User N = 6636 | Regular user | |
N = 4616 | N = 990 | N = 1597 | ||
Baseline characteristic | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) |
Age, years | 41.7 (12.7) | 53.1 (11.7) | 44.0 (12.9) | 54.2 (11.5) |
Race and ethnicity, No. (%) | ||||
 Non-Hispanic white | 4269 (92.5) | 888 (89.7) | 5860 (88.3) | 1366 (85.5) |
 Other | 274 (5.9) | 94 (9.5) | 694 (10.5) | 223 (14.0) |
 Missing | 73 (1.6) | 8 (0.8) | 82 (1.2) | 8 (0.5) |
Cigarette smoking, No. (%) | ||||
 Never | 2688 (58.2) | 575 (58.1) | 3862 (58.2) | 896 (56.1) |
 Former | 1088 (23.6) | 267 (27.0) | 1705 (25.7) | 492 (30.8) |
 Current | 469 (10.2) | 91 (9.2) | 663 (10.0) | 140 (8.8) |
 Missing | 371 (8.0) | 57 (5.8) | 406 (6.1) | 69 (4.3) |
Alcohol consumption, No. (%) | ||||
 Never | 1852 (40.1) | 532 (53.7) | 2943 (44.4) | 841 (52.7) |
 Former | 755 (16.4) | 129 (13.0) | 1062 (16.0) | 220 (13.8) |
 Current | 1924 (41.7) | 318 (32.1) | 2514 (37.9) | 513 (32.1) |
 Missing | 85 (1.8) | 11 (1.1) | 117 (1.8) | 23 (1.4) |
Hormone therapy use, No. (%) | ||||
 Never | 3717 (80.5) | 542 (54.8) | 5255 (79.2) | 895 (56.0) |
 Former | 409 (8.9) | 191 (19.3) | 758 (11.4) | 361 (22.6) |
 Current | 430 (9.3) | 230 (23.2) | 522 (7.9) | 290 (18.2) |
 Missing | 60 (1.3) | 27 (2.7) | 101 (1.5) | 51 (3.2) |
Hormonal birth control use, No. (%) | ||||
 Never | 635 (13.8) | 253 (25.6) | 1224 (18.4) | 480 (30.1) |
 Former | 3043 (65.9) | 659 (66.6) | 4373 (65.9) | 1015 (63.6) |
 Current | 900 (19.5) | 59 (6.0) | 973 (14.7) | 69 (4.3) |
 Missing | 38 (0.8) | 19 (1.9) | 66 (1.0) | 33 (2.1) |
COX-2 inhibitors, No. (%) | ||||
 Non-regular user | 4227 (91.6) | 814 (82.2) | 6140 (92.5) | 1366 (85.5) |
 Regular user | 358 (7.8) | 161 (16.3) | 428 (6.5) | 199 (12.5) |
 Missing | 31 (0.7) | 15 (1.5) | 68 (1.0) | 32 (2.0) |
Ibuprofen and other NSAIDsc, No. (%) | ||||
 Non-regular user | 3911 (84.7) | 714 (72.1) | 5512 (83.1) | 1139 (71.3) |
 Regular user | 682 (14.8) | 258 (26.1) | 1063 (16.0) | 426 (26.7) |
 Missing | 23 (0.5) | 18 (1.8) | 61 (0.9) | 32 (2.0) |
Acetaminophen, No. (%) | ||||
 Non-regular user | 3859 (83.6) | 740 (74.8) | 5597 (84.3) | 1214 (76.0) |
 Regular user | 737 (16.0) | 238 (24.0) | 985 (14.8) | 361 (22.6) |
 Missing | 20 (0.4) | 12 (1.2) | 54 (0.8) | 22 (1.4) |
BOADICEA 1-year risk score, % | 0.51 (0.71) | 0.68 (0.85) | 0.50 (0.72) | 0.64 (0.83) |
Mutation carrier status, No. (%) | ||||
 Non-carrierd | 4070 (88.2) | 915 (92.4) | 5739 (86.5) | 1440 (90.2) |
 BRCA1 mutation carrier | 292 (6.3) | 37 (3.7) | 500 (7.5) | 84 (5.3) |
 BRCA2 mutation carrier | 254 (5.5) | 38 (3.8) | 397 (6.0) | 73 (4.6) |